Aptus Pharma (544529)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 38.20% indicates highly efficient capital deployment.
• Sales growth of 47.34% and profit growth of 33.59% show strong momentum.
• Piotroski F-Score of 7/9 suggests good financial health.
• PEG ratio of 1.30 implies reasonable valuation relative to near-term growth.

Concerns

• P/E of 52.70 leaves little margin of safety if growth decelerates.
• Zero dividend means no income cushion for investors.
• Lack of data on debt, book value, and promoter holding creates uncertainty.
• Very small scale (quarterly sales of ₹14 Cr) makes it vulnerable to volatility.

AI Analysis

When I look at Aptus Pharma, I see a small, fast-growing pharmaceutical business with an impressive return on capital. A ROCE of 38.20% is the kind of number that would make any investor sit up and take notice. Sales are growing at 47.34% and profits at 33.59% — that’s a compounding engine, albeit from a small base. The latest quarter shows sales of ₹14 Cr and net profit of ₹2 Cr, so we’re talking about a very early-stage story. At ₹271.95, the market cap is just ₹187 Cr, which means the market expects continued high growth. The P/E of 52.70 is steep; Graham would call that speculative unless growth persists. Still, the PEG ratio of 1.30 suggests the price is not absurd if the growth trajectory holds. The Piotroski F-Score of 7/9 indicates solid financial health for a company this size — no obvious red flags in profitability, leverage, or efficiency. But I have reservations. There’s no dividend — that’s fine for a reinvesting grower, but it means shareholders rely entirely on capital appreciation. More importantly, I have no data on debt, book value, or promoter holding. That makes it hard to judge financial stability or alignment with minority shareholders. The business appears to be a fast grower with a possible niche, but I cannot identify a durable moat from these numbers alone. Is it pricing power, regulatory barriers, or just a tailwind? At this size, one bad quarter or a regulatory setback could hit the stock hard. I’d want to see consistent cash conversion and a stronger balance sheet before putting my name on it. For now, it’s a promising small-cap pharma, but I’d keep the position small and watch closely.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer